NasdaqGM:SMMTBiotechs
Summit Therapeutics (SMMT): Evaluating Valuation After Fresh Analyst Optimism on Ivonescimab and HARMONi-3 Trial
Summit Therapeutics (SMMT) is back on investors’ radar after fresh bullish commentary from Cantor Fitzgerald and a rating upgrade from Barclays, both zeroing in on ivonescimab and the upcoming HARMONi-3 phase 3 trial.
See our latest analysis for Summit Therapeutics.
The bullish focus on ivonescimab and HARMONi-3 has coincided with a 7.61% one-month share price return to $17.82, while the three-year total shareholder return of 385.56% underscores how momentum has transformed longer-term...